MRNA stock news · Moderna Inc.
Get alerts for MRNA
Follow Moderna Inc. (MRNA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRNAMerck's stock went up after it reported better-than-expected earnings and strong sales for new products.
Good for MRNAModerna’s partnered cancer-treatment trial with Merck produced its first positive Phase 3 results. This is progress for a treatment still under development, not a report of sales.
Moderna and Merck share results from their Phase 3 trial for the cancer vaccine Intismeran Autogene.
Good for MRNAModerna reported trial results showing its cancer treatment reduced the risk of recurrence or death. That is encouraging for the company, though the treatment is still investigational.
OpenAI has purchased a biotech company to help scientists create medicines more quickly.
NeutralModerna is named as an OpenAI collaborator, but the story reports no new project or result for it. A separate AI study did not show whether designed proteins could neutralize venom, so the article does not change Moderna's outlook.
The Nasdaq 100 dropped as Micron, SanDisk, and CoreWeave lost value today.
NeutralModerna gave back part of a roughly 6% rise from the prior day as investors shifted among sectors. The story reports no new company development, so this trading move does not change its business outlook.
Stephen King criticizes Trump’s new press secretary for her old posts about vaccines and election claims.
NeutralThe story mentions Moderna’s recent share rise but reports no new company development or link between the dispute and Moderna’s business.
Moderna's stock price just reached its highest point in a year. What's going on?
Good for MRNAModerna joins the Nasdaq-100 as a national cancer-vaccine effort puts mRNA research back in focus. Its trial results add support, though the program starts slowly.
Today, big investors are making moves with 10 health care stocks.
NeutralModerna's call trade was labeled bullish. The report gives no new company result or plan, so this trading activity does not change its outlook.
Moderna, Vaxcyte, and Novavax are getting attention after a possible pneumonic plague case in Russia worries people.
NeutralModerna was grouped with vaccine stocks after a suspected plague case, but the report does not link it to Moderna's vaccines. It adds no clear change to the company's outlook.
People betting against Novavax are worried as fears of a plague in Russia grow.
NeutralModerna shares rose as vaccine stocks gained on outbreak fears. Plague is unconfirmed, and the story reports no new Moderna sales or orders, so its business outlook is unchanged.
Today, big trades were spotted in 4 health care stocks.
NeutralMRNA had a put option trade labeled neutral. The article gives no new business results, so this trade does not change its outlook.
Moderna says some directors and officers are leaving, while new ones are being chosen and hired.
NeutralModerna filed an 8-K listing officer and director matters, but the supplied text gives no specific changes. It does not change the outlook for Moderna.
Moderna's stock hits a new high of $208.90 after good news about its trials.
NeutralModerna's cancer-drug research is set for a late-October presentation, but this story gives no trial findings. It adds no new evidence about the drug's effect in patients.
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine, and other big stocks climbed on Wednesday.
Good for MRNAModerna had three abstracts accepted for presentation at ESMO 2026 about its individualized neoantigen therapy, which supports the company's scientific progress and pipeline value.
Big investors are making moves in 10 health care stocks today.
Good for MRNAModerna saw a large, short-dated call sweep. I read the trade as bullish because buyers aggressively bought 4,545 contracts at the $180 strike.
Pete Buttigieg calls out corruption in U.S. politics, saying big companies are taking over elections and getting what they want.
NeutralModerna was included by implication in the 'Big Pharma' criticism. This broad political commentary contains no new legal or business action, so it does not change Moderna's outlook.
Congresswoman Maria Elvira Salazar buys stocks in Elon Musk's SpaceX and Warren Buffett's Berkshire Hathaway.
Good for MRNAThe story ties Moderna to a successful Phase 3 melanoma vaccine that uses Merck’s Keytruda, which is positive news for Moderna’s clinical progress.
New legislation introduced by Congressman targets President's stock trading practices: ‘Divest or resign’.
NeutralCongressman Eugene Vindman has introduced a bill aimed at banning stock trading by the President and members of Congress, highlighting concerns over potential conflicts of interest, particularly in light of President Trump's extensive trading history.
Will CrowdStrike Surge Beyond 15%? Discover 10 Leading Analyst Predictions for Thursday.
NeutralPrice-target increase is offset by an analyst downgrade to Sell, producing mixed signals with no clear net effect.
Dolly Parton's commitment to philanthropy likely prevented her from achieving billionaire status, as she stated, "I don’t work for money, never did.
NeutralDolly Parton, a legendary singer and philanthropist, passed away at the age of 80, leaving behind a significant philanthropic legacy and a net worth of $450 million, primarily from her ownership stake in Dollywood and music publishing rights.
Following a remarkable surge, Moderna shares fell on Monday: What’s the reason behind this shift?
NeutralModerna's stock has declined following a historic rally fueled by successful Phase 3 trial results for its mRNA cancer vaccine. This pullback may indicate profit-taking after a substantial increase in market capitalization and analyst upgrades.
This week, 5 stocks, including MRNA, SPCX, and MSTR, captured the attention of investors.
NeutralModerna's announcement of successful Phase 3 trial results for its mRNA cancer vaccine has generated significant retail interest and a sharp stock price increase, while Walmart's strong earnings report and raised guidance reflect solid operational performance, both contributing to positive market sentiment.
Moderna's rise to prominence due to COVID-19 may be overshadowed by its future in cancer treatment.
Good for MRNAModerna's announcement of a successful Phase 3 trial for its personalized mRNA cancer vaccine in collaboration with Merck marks a pivotal moment for the company, potentially revitalizing its revenue prospects post-COVID-19. This breakthrough not only enhances Moderna's reputation in the biotech space but also positions it as a leader in innovative cancer treatments, likely boosting investor…
Moderna's shares plummet 25%, potentially marking the company's most significant decline ever.
Bad for MRNAModerna's stock experienced a dramatic drop of 25% following a record increase of nearly 177% after announcing positive trial results for its cancer vaccine. This volatility reflects investor sentiment and market reactions to the company's performance and short interest levels.
Analyst highlights potential for Moderna's Intismeran in oncology, akin to Keytruda.
NeutralModerna's stock is experiencing volatility following a significant rally, but new analyst insights suggest a strong future for its Intismeran therapy, particularly in oncology. The upgrade from William Blair highlights a substantial increase in projected sales, which could bolster investor confidence and drive stock performance.
Pharma Bro acknowledges 'fooling around' with MRNA short at $80 prior to its 177% surge after cancer vaccine trial results—‘I wager many individuals were let go.’
NeutralModerna's stock experienced a dramatic increase of 177% after the announcement of a breakthrough in its cancer vaccine trials, catching many investors off guard and leading to significant losses for those who were shorting the stock. This unexpected rally highlights the volatility and potential for rapid changes in sentiment within the biotech sector.